Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables: 2010-2025

Historic Change in Receivables for China Pharma Holdings (CPHI) over the last 15 years, with Sep 2025 value amounting to $117,491.

  • China Pharma Holdings' Change in Receivables fell 29.77% to $117,491 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,669, marking a year-over-year increase of 47.75%. This contributed to the annual value of $197,708 for FY2024, which is 78.92% down from last year.
  • As of Q3 2025, China Pharma Holdings' Change in Receivables stood at $117,491, which was up 471.29% from $20,566 recorded in Q2 2025.
  • China Pharma Holdings' Change in Receivables' 5-year high stood at $434,306 during Q1 2023, with a 5-year trough of -$258,130 in Q1 2022.
  • In the last 3 years, China Pharma Holdings' Change in Receivables had a median value of $164,670 in 2025 and averaged $130,769.
  • Per our database at Business Quant, China Pharma Holdings' Change in Receivables tumbled by 330.95% in 2021 and then skyrocketed by 578.17% in 2022.
  • Over the past 5 years, China Pharma Holdings' Change in Receivables (Quarterly) stood at $393,662 in 2021, then tumbled by 72.75% to $107,286 in 2022, then surged by 239.52% to $364,258 in 2023, then crashed by 41.54% to $212,942 in 2024, then declined by 29.77% to $117,491 in 2025.
  • Its last three reported values are $117,491 in Q3 2025, $20,566 for Q2 2025, and $164,670 during Q1 2025.